Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 1

2996 - mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109)


09 Sep 2017


Gastrointestinal tumours, colorectal 1


Cytotoxic Therapy;  Colon and Rectal Cancer


Michael Geissler


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


M. Geissler1, U.M. Martens2, R. Knorrenschield3, J. Greeve4, A. Florschuetz5, A. Tannapfel6, S. Wessendorf1, T. Seufferlein7, S. Kanzler8, V. Heinemann9, S. Held10, A. Reinacher-Schick11

Author affiliations

  • 1 Oncology, Hematology, Gastroenterology, Infectious Diseases, Klinikum Esslingen, 73730 - Esslingen/DE
  • 2 Medizinische Klinik Iii, SLK-Kliniken Heilbronn GmbH, 74078 - Heilbronn/DE
  • 3 Hämatologie/onkologie, Universitätsklinkum Marburg, Marburg/DE
  • 4 Med. Klinik I, St. Vincenz Krankenhaus, Paderborn/DE
  • 5 Innere Medizin, Klinikum Dessau, Dessau/DE
  • 6 Pathologie, Ruhr Universität, Bochum/DE
  • 7 Department Of Internal Medicine I  , Ulm University, Ulm/DE
  • 8 Med. Klinik Ii, Leopoldina Krankenhaus Medizinische Klinik II, 97422 - Schweinfurt/DE
  • 9 Dept. Of Medicine Iii, Ludwig Maximilians University - Grosshadern, 81377 - München/DE
  • 10 Clinassess Gmbh, ClinAssess GmbH, Leverkusen/DE
  • 11 Hämatologie/onkologie, Ruhr University Bochum Medizinische Universitätsklinik, 44892 - Bochum/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2996


Triple chemotherapy with an anti-EGFR reported promising activity with some safety concerns in single arm phase II trials. The randomized VOLFI trial evaluated activity and safety of mFOLFOXIRI + panitumumab versus FOLFOXIRI in ECOG 0-1, primarily non-resectable mCRC patients.


Prospective 2:1 randomized, multi-center, phase II trial comparing mFOLFOXIRI (Oxaliplatin 85 mg/m2, Irinotecan 150 mg/m2, 5-FU 3000mg/m2 cont. 48h, LV 200 mg/m2) + Panitumumab 6 mg/KG (arm A) with FOLFOXIRI (Ox 85 mg/m2, Iri 165 mg/m2, 5-FU 3200mg/m2 cont. 48h, LV 200 mg/m2; arm B), both arms q2w. Cohort 1: irresectable mCRC; cohort 2: chance of secondary resection of metastatic lesions. Primary endpoint was ORR, secondary endpoints were secondary resection rate (cohort 2), DCR, PFS, OS, toxicity, quality of life. Financially supported by an unrestricted grant from Amgen.


A total of 96 patients were randomized (63 arm A, 33 arm B). In arm A and B 20 (31.7%) and 11 (33.3%) patients belonged to cohort 2, respectively. ORR was 85.7% in arm A and 54.5% in arm B (p = 0.0013, OR 5.000; 95%-CI 1.870-13.370). DCR was 96.8% in arm A and 78.8% in arm B (p = 0.0071, OR 8.212). In arm A and B 53 (84,1%) and 25 (75.8%) tumors were left sided, 10 (15.9%) and 6 (18.2%) were located in the right colon, respectively. ORR in Arm A was 90.6% versus 60.0% (p = 0.0288, OR 6.400) and in Arm B 60.0% versus 50% (p=n.s.) for left and right located CRC, respectively. ORR between arms A and B comparing left and right sided CRC was 90.6% versus 60.0% (p = 0.0039, OR 6.400; 95%-CI 1.889-21.679) and 60.0% versus 50.0% (p= n.s.), respectively. Secondary resections in cohort 2 were 60% (n = 12) and 36.4% (n = 4) in arms A and B, respectively. Serious adverse advents grade 3-5 occured in 45.3% and 24.2% in arms A and B, respectively (p = 0.0496).


mFOLFOXIRI plus panitumumab results in significantly higher response rates compared to FOLFOXIRI in RAS wild-type mCRC. Response rates, however, are differential according to tumor sidedness. High secondary resection rates were observed. Toxicity is manageable in younger fit patients with ECOG 0-1. PFS, OS, QL and TR data are still immature and will be presented at the meeting.

Clinical trial identification


Legal entity responsible for the study





M. Geissler: Honoraria and advisory board from Amgen All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.